Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408461 | 0.84 | PTGS1 (0.36) | EPHX1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL361556 | 0.84 | PTGS1 (0.40) | EPHX1PTGS1PTGS2LMNACYP2C9 | |
| Toliodium SCHEMBL1155683 | 0.84 | ACHE (0.37) | — | |
| Hydrochloric Acid SCHEMBL31093481 | 0.82 | PTGS1 (0.39) | EPHX1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL29408470 | 0.81 | PTGS1 (0.36) | EPHX1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL29351331 | 0.81 | PTGS1 (0.36) | EPHX1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL133838 | 0.80 | SCN5A (0.31) | — | |
| SCHEMBL1155415 | 0.78 | ACHE (0.34) | LMNANFKB1TSHR | |
| SCHEMBL4644260 | 0.77 | — | — | |
| SCHEMBL284111 | 0.77 | PTGS1 (0.45) | EPHX1PTGS1PTGS2LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225395-A1 | Thermally stable cationic photocurable compositions | WOLF JEAN-PIERRE | 2007-09-27 | — | — | US | claimed |
| US-20050165141-A1 | Thermally stable cationic photocurable compositions | CIBA SPECIALTY CHEMICALS CORP. | 2005-07-28 | — | — | US | claimed |
| EP-2076563-B1 | THERMALLY STABLE CATIONIC PHOTOCURABLE COMPOSITIONS | BASF SE (DE) | 2016-08-17 | — | — | EP | disclosed |
| US-8084522-B2 | Thermally stable cationic photocurable compositions | BASF SE (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8003169-B2 | Using photoinitiators; discharging plasma ; applying to three-dimensional substrate | BASF SE (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20100304284-A1 | THERMALLY STABLE CATIONIC PHOTOCURABLE COMPOSITIONS | IGM GROUP B.V. (NL) | 2010-12-02 | — | — | US | disclosed |
| EP-1497338-B1 | CURING OF COATINGS INDUCED BY PLASMA | BASF SE (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-2076563-A1 | THERMALLY STABLE CATIONIC PHOTOCURABLE COMPOSITIONS | Ciba Holding Inc. (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008049743-A1 | THERMALLY STABLE CATIONIC PHOTOCURABLE COMPOSITIONS | CIBA HOLDING INC. (CH) | 2008-05-02 | — | — | WO | disclosed |
| US-20070249484-A1 | Process for the Photoactivation and use of a Catalyst by an Inverted Two-Stage Procedure | CIBA SPECIALTY CHEMICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070225395-A1 | Thermally stable cationic photocurable compositions | WOLF JEAN-PIERRE | 2007-09-27 | — | — | US | disclosed |
| EP-1709099-A2 | THERMALLY STABLE CATIONIC PHOTOCURABLE COMPOSITIONS | Ciba Specialty Chemicals Holding Inc. (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006008251-A2 | PROCESS FOR THE PHOTOACTIVATION AND USE OF A CATALYST BY AN INVERTED TWO-STAGE PROCEDURE | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005070989-A2 | THERMALLY STABLE CATIONIC PHOTOCURABLE COMPOSITIONS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165141-A1 | Thermally stable cationic photocurable compositions | CIBA SPECIALTY CHEMICALS CORP. | 2005-07-28 | — | — | US | disclosed |
| US-20050129859-A1 | Curing of coating induced by plasma | CIBA CORPORATION | 2005-06-16 | — | — | US | disclosed |
| EP-1497338-A2 | CURING OF COATINGS INDUCED BY PLASMA | Ciba SC Holding AG (CH) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089479-A2 | CURING OF COATINGS INDUCED BY PLASMA | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-10-30 | — | — | WO | disclosed |
| US-20010036591-A1 | Iodonium salts as latent acid donors | IGM GROUP B.V. (NL) | 2001-11-01 | — | — | US | disclosed |
| US-6306555-B1 | RADIATION-SENSITIVE COMPOSITION COMPRISING CATIONICALLY OR ACID-CATALYTICALLY POLYMERISABLE OR CROSSLINKABLE COMPOUND OR COMPOUND THAT INCREASES ITS SOLUBILITY IN DEVELOPER UNDER ACTION OF ACID, AND AT LEAST ONE DIARYLIODONIUM SALT | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249484-A1 | Process for the Photoactivation and use of a Catalyst by an Inverted Two-Stage Procedure | INF2, CRY2, CCNT2 | EPHX1 1872/4885PTGS1 3875/4885PTGS2 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.